Related Experiment Video
Updated: May 17, 2026
Transmembrane Domain Oligomerization Propensity determined by ToxR Assay
Published on: May 26, 2011
Assessing the effect of RET transmembrane domain mutations in receptor self-association capability using the in vivo
M Benej1, S Fekecsova, M Poturnajova
1Institute of Virology, Bratislava.
Abstract:
Mutations of c-RET proto-oncogene with a unique localization within the human transmembrane receptor represent a challenge for contemporary molecular oncology techniques. RET transmembrane domain (TMD)-driven dimerization of the receptor leads to its permanent activation that eventually results in the development of medullary thyroid neoplasia. In this study, we describe the employment of the TOXCAT system which enables to investigate mutation-induced alterations in the strength of RET TMD dimerization in vivo. We suggest an improvement of the method by adding reporter gene quantification at the mRNA levels as a support to the commonly used reporter protein level. We have investigated possible changes in RET TMD dimerization in case of two germline RET TMD mutations found in in several individual cases and MEN2 families worldwide, p.Ala641Ser and p.Ser649Leu. According to our results, substitution of Ser-649 residue by leucine, found as a result of germline mutation, caused a significant decrease of RET TMD self-association in comparison to RET wild-type transmembrane domain. The impaired ability of self-association suggests a novel, yet unknown mechanism of tyrosine kinase domain activation, possibly independent of RET homodimerization.
Insights
Mutations in the RET transmembrane domain (TMD) can cause medullary thyroid cancer. This study used the TOXCAT system to show a specific RET TMD mutation (Ser649Leu) weakens receptor dimerization, suggesting a new activation pathway.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The RET proto-oncogene's transmembrane domain (TMD) mutations drive medullary thyroid neoplasia via constitutive receptor activation.
- Understanding RET TMD dimerization is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate mutation-induced alterations in RET TMD dimerization strength in vivo.
- To propose an improved TOXCAT system incorporating mRNA level reporter gene quantification.
Main Methods:
- Employment of the TOXCAT system to assess RET TMD dimerization in vivo.
- Investigation of two germline RET TMD mutations: p.Ala641Ser and p.Ser649Leu.
- Quantification of reporter gene expression at both protein and mRNA levels.
Main Results:
- The p.Ser649Leu mutation significantly decreased RET TMD self-association compared to wild-type.
- This impaired dimerization suggests a novel, potentially homodimerization-independent, tyrosine kinase domain activation mechanism.
Conclusions:
- The TOXCAT system effectively analyzes RET TMD dimerization.
- The p.Ser649Leu mutation's effect on dimerization offers new insights into RET-driven oncogenesis.
- Further research is warranted to elucidate the novel activation mechanism.
